Skip to main content
Livermore
Livermore
ZHEN

Theseus Pharmaceuticals, Inc.

THRXDelisted Feb 14, 2024
Industry
Pharmaceutical Preparations
SEC CIK
0001745020

Theseus Pharmaceuticals, Inc. was delisted on Feb 14, 2024; its insiders filed their last Form 4 on Feb 14, 2024; 70 institutions reported holding it in 13F filings for Q4 2023, worth $145.8M in total; no superinvestor held it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Theseus Pharmaceuticals, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Theseus Pharmaceuticals, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Theseus Pharmaceuticals, Inc.
NameTitleLast reported holdingLast filingFilings, past year
OrbiMed Advisors LLCDirector, 10% Owner0IndirectFeb 14, 20240
OrbiMed Capital GP VII LLCDirector, 10% Owner0IndirectFeb 14, 20240
OrbiMed Genesis GP LLCDirector, 10% Owner0IndirectFeb 14, 20240
Hayden Donald J JrDirector0Feb 14, 20240
Gordon Carl LDirector, 10% Owner0IndirectFeb 14, 20240
Stein Steven HDirector–Feb 14, 20240
Dukes Iain D.Director0Feb 14, 20240
Yi KathyDirector–Feb 14, 20240
Dahms Bradford D.President and CFO0Feb 14, 20240
Shakespeare WilliamSee Remarks639,408Nov 7, 20230
Tananbaum James B.10% Owner1,385,825IndirectJul 19, 20230
Foresite Capital Fund V, L.P.10% Owner1,385,825IndirectJul 19, 20230
Foresite Capital Opportunity Fund V, L.P.10% Owner1,385,825IndirectJul 19, 20230
Foresite Capital Management V, LLC10% Owner1,385,825IndirectJul 19, 20230
Foresite Capital Opportunity Management V, LLC10% Owner1,385,825IndirectJul 19, 20230
Clackson Timothy PPresident and CEO351,030Mar 2, 20230
Kerstein DavidChief Medical Officer–Mar 2, 20230
Rivera VictorChief Scientific Officer–Mar 2, 20230
Dalgarno DavidChief Technical Officer–Feb 23, 20220
Ariad Pharmaceuticals Inc10% Owner1,615,427IndirectOct 15, 20210
Takeda Pharmaceutical Co Ltd10% Owner1,615,427IndirectOct 15, 20210
Rock Springs Capital Management LP10% Owner599,320IndirectOct 14, 20210
Rock Springs Capital Master Fund LP10% Owner599,320IndirectOct 14, 20210
Rock Springs Capital LLC10% Owner599,320IndirectOct 14, 20210
Stampacchia OtelloOther: Former 10% owner711,479Oct 14, 20210
Paster Anne-MariOther: Former 10% owner711,479Oct 14, 20210
Nessi ClaudioOther: Former 10% owner711,479Oct 14, 20210
Omega Fund VI, L.P.Other: Former 10% owner711,479Oct 14, 20210
Omega Fund VI GP Manager, Ltd.Other: Former 10% owner711,479Oct 14, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jul 19, 2023 (view filing)4:15 PM ETJul 172 daysOrbiMed Advisors LLC and 2 othersDirector, 10% OwnerPPurchase+479.9K$3.05+$1.46M+281.2%650.6K after2 lotsDuplicate filing
Jul 19, 2023 (view filing)2:54 PM ETJul 172 daysTananbaum James B. and 4 others10% OwnerPPurchase+700.0K$2.97+$2.08M+102.1%1.39M after2 lots
Jul 19, 2023 (view filing)Jul 172 daysGordon Carl LDirector, 10% OwnerPPurchase+479.9K$3.05+$1.46M+281.2%650.6K after2 lots
Jan 3, 2023 (view filing)4:24 PM ETDec 29, 20225 daysTananbaum James B. and 4 others10% OwnerPPurchase+500.0K$5.00+$2.50M+70.5%1.21M after2 lots
Jan 3, 2023 (view filing)Dec 29-30, 20225 daysHayden Donald J JrDirectorPPurchase+10.0K$5.00+$50.0KNew position10.0K after2 lots
Dec 1, 2022 (view filing)Nov 301 dayDahms Bradford D.Chief Financial OfficerPPurchase+1.50K$6.66+$10.0K+32.4%6.14K after
Nov 14, 2022 (view filing)Nov 113 daysClackson Timothy PPresident and CEOPPurchase+2.50K$6.80+$17.0K+0.7%351.0K after
Nov 9, 2022 (view filing)4:25 PM ETNov 72 daysOrbiMed Advisors LLC and 2 othersDirector, 10% OwnerPPurchase+192.0K$5.21+$1.00M+1.2%16.7M afterDuplicate filing
Nov 9, 2022 (view filing)Nov 72 daysGordon Carl LDirector, 10% OwnerPPurchase+192.0K$5.21+$1.00M+1.2%16.7M after
Jan 21, 2022 (view filing)7:18 PM ETJan 19-212 daysOrbiMed Advisors LLC and 2 othersDirector, 10% OwnerPPurchase+158.4K$9.97+$1.58M+1.0%16.5M after3 lotsDuplicate filing
Jan 21, 2022 (view filing)Jan 19-212 daysGordon Carl LDirector, 10% OwnerPPurchase+158.4K$9.97+$1.58M+1.0%16.5M after3 lots
Jan 13, 2022 (view filing)7:18 PM ETJan 11-132 daysOrbiMed Advisors LLC and 2 othersDirector, 10% OwnerPPurchase+44.7K$9.90+$442.8K+0.3%16.4M after4 lotsDuplicate filing
Jan 13, 2022 (view filing)Jan 11-132 daysGordon Carl LDirector, 10% OwnerPPurchase+44.7K$9.90+$442.8K+0.3%16.4M after4 lots
Dec 22, 2021 (view filing)Dec 211 dayClackson Timothy PPresident and CEOPPurchase+2.60K$9.76+$25.4K+0.8%348.5K after
Dec 22, 2021 (view filing)Dec 211 dayDahms Bradford D.Chief Financial OfficerPPurchase+1.97K$10.15+$20.0KNew position1.97K after
Oct 14, 2021 (view filing)5:00 PM ETOct 122 daysRock Springs Capital Management LP and 2 others10% OwnerPPurchase+250.0K$16.00+$4.00M+71.6%599.3K after
Oct 14, 2021 (view filing)5:00 PM ETOct 122 daysOrbiMed Advisors LLC and 2 othersDirector, 10% OwnerPPurchase+625.0K$16.00+$10.0MNew position499.1K after2 lotsDuplicate filing
Oct 14, 2021 (view filing)4:40 PM ETOct 122 daysStampacchia Otello and 4 othersOther: Former 10% ownerPPurchase+187.5K$16.00+$3.00M+35.8%711.5K after
Oct 14, 2021 (view filing)Oct 122 daysGordon Carl LDirector, 10% OwnerPPurchase+625.0K$16.00+$10.0MNew position499.1K after2 lots
Oct 14, 2021 (view filing)Oct 122 daysShakespeare WilliamSee RemarksPPurchase+625$16.00+$10.0K+0.2%388.9K after